ImmunoGen, Inc. (NASDAQ:IMGN) VP Craig Barrows sold 37,050 shares of the company’s stock in a transaction that occurred on Friday, September 15th. The shares were sold at an average price of $6.81, for a total value of $252,310.50. Following the completion of the transaction, the vice president now directly owns 51,100 shares of the company’s stock, valued at $347,991. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

ImmunoGen, Inc. (NASDAQ:IMGN) traded down 1.45% during midday trading on Friday, hitting $6.80. The stock had a trading volume of 5,935,568 shares. ImmunoGen, Inc. has a 12-month low of $1.51 and a 12-month high of $8.84. The company has a 50-day moving average price of $6.56 and a 200-day moving average price of $5.16. The company’s market cap is $609.26 million.

ImmunoGen (NASDAQ:IMGN) last posted its quarterly earnings data on Friday, July 28th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.07. The business had revenue of $39.02 million for the quarter, compared to analysts’ expectations of $30.59 million. During the same quarter in the prior year, the firm earned ($0.53) earnings per share. ImmunoGen’s revenue for the quarter was up 426.6% compared to the same quarter last year. Equities analysts anticipate that ImmunoGen, Inc. will post ($0.74) EPS for the current year.

TRADEMARK VIOLATION WARNING: This piece of content was originally posted by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another website, it was copied illegally and republished in violation of international copyright and trademark legislation. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/09/15/immunogen-inc-imgn-vp-craig-barrows-sells-37050-shares.html.

Hedge funds and other institutional investors have recently modified their holdings of the company. Arrowstreet Capital Limited Partnership bought a new stake in shares of ImmunoGen in the 2nd quarter valued at approximately $102,000. Envestnet Asset Management Inc. increased its holdings in shares of ImmunoGen by 2.8% in the 1st quarter. Envestnet Asset Management Inc. now owns 27,761 shares of the biotechnology company’s stock valued at $107,000 after acquiring an additional 743 shares during the last quarter. Gould Asset Management LLC CA bought a new stake in shares of ImmunoGen in the 2nd quarter valued at approximately $107,000. Intl Fcstone Inc. bought a new stake in shares of ImmunoGen in the 2nd quarter valued at approximately $115,000. Finally, Acadian Asset Management LLC bought a new stake in shares of ImmunoGen in the 1st quarter valued at approximately $117,000. Institutional investors and hedge funds own 84.66% of the company’s stock.

A number of equities analysts recently issued reports on the company. Jefferies Group LLC reaffirmed a “buy” rating and issued a $6.00 price target on shares of ImmunoGen in a report on Wednesday, June 28th. Cantor Fitzgerald reaffirmed a “hold” rating and issued a $5.00 price target on shares of ImmunoGen in a report on Wednesday, May 24th. Canaccord Genuity set a $6.00 price target on ImmunoGen and gave the company a “buy” rating in a report on Friday, May 19th. Cowen and Company reaffirmed a “hold” rating on shares of ImmunoGen in a report on Tuesday, August 29th. Finally, William Blair reaffirmed an “outperform” rating on shares of ImmunoGen in a report on Monday, June 26th. Two research analysts have rated the stock with a sell rating, three have assigned a hold rating and six have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $8.01.

ImmunoGen Company Profile

ImmunoGen, Inc is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. The Company is engaged in the discovery of monoclonal antibody-based anticancer therapeutics. An ADC with the Company’s technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target.

Receive News & Ratings for ImmunoGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoGen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.